Audit: QRS - sh-Polypeptide-4 for Hair Regrowth
Audit conducted on 24/08/2026 04:11 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values, time-to-effect values, tier items, gate items, biomarker targets and cadence trace to ER Therapeutic Protocol, Practical Considerations, Discontinuation & Cycling, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No validated protocol”, “No effect demonstrated, so no time course exists”, “None established”, “No established target” all mirror the ER wording. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolutes; the benefit is kept bounded by “within multi-factor preparations”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates come only from Key Interactions & Contraindications; no modifying factor is promoted into a gate or risk tier. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs or brand names appear; drug names (imatinib, minoxidil, cetirizine, etc.) all appear in the ER interaction bullets. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Same restrained, evidence-bounded register and British spelling as the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents thresholds and measurable endpoints without hedging or discouraging language. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells describe what protocols do, not what the reader must do. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Descriptive framing throughout (“in most protocols”, “usual trial threshold”). |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending verbs present. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to decision gates and biomarkers where they are load-bearing. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every field is a condensed clause or short sentence pair. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for “you”/”your”/”we”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal functional ranges and trichoscopic endpoints assume a proactive, measurement-driven reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twice-daily dosing over 6-12 months, 4-weekly standardised photography and a seven-marker panel are presented without softening. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification to a general-population reading level. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance foregrounds the delivery-barrier and funding-bias issues that matter to a discerning self-directed user. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not occur. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Mast-cell activation”, “urticarial skin reactions”, “contact sensitisation”, “hyperpigmentation” used throughout. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate heads, tier labels and column headers are byte-identical to the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template spans present; the repeatable marker_#_* and qualitative_item_# spans are expanded to 7 marker rows and 5 qualitative items. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A full diff against the template shows changes only inside variable spans; head, style block, website="…" spans, comments and footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section drawn on by the QRS is empty; absent benefit/risk tiers are handled under 12.5 / 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Conventional approach”, “Procedural approach”, “Baseline biomarkers”, “Time to effect”, “Duration”, “Post-discontinuation shedding” all match the ER bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; monitoring row labels match the ER biomarker table entries. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan returns no emoji characters. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Section budgets respected: 3 protocol cells, 3 time cells, 6 contraindications, 8 interactions, 7 marker rows, 5 qualitative items, all as single condensed clauses. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after the doctype and before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” line 3, closing “—” line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Contained entirely within the HTML comment; no duplicate rendering elsewhere. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: sh_polypeptide_4_hair_2026-0824-0218_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 matches the QRS.md badge version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0824-0342. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: sh_polypeptide_4_hair_2026-0824-0218_Opus_QRS.html matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “sh-Polypeptide-4 for Hair Regrowth - Quick Reference Sheet”; no characters requiring entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “sh-Polypeptide-4 for Hair Regrowth” (line 417) matches canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0824-0342 → “08/24/2026”. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” list was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all four Conclusion paragraphs: what it is, the colour-vs-thickness limit, the absent single-agent evidence, the barrier problem and the funding bias. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion sentence (ER lines 417-421). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “laboratory-made copy of a natural human signalling protein” replaces “recombinant”; no acronyms, no kDa figure, no KIT terminology. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial named or referenced. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers appear. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER’s “Populations who should avoid sh-Polypeptide-4” list (ER lines 269-276). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the stop_items span (lines 570-577). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale stripped (“…, where no exposure data of any kind exist” → “Pregnancy and lactation”); no dashes carrying trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “above 20 ng/mL”, “five or more atypical moles on the scalp or neck”, “more than standard-dose antihistamines”, “in the active inflammatory phase” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER contraindication list uses no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies six such populations and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the eight ER interaction bullets (ER lines 253-267). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight interactions present; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span (lines 583-592). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity notes and mechanistic rationale from each ER bullet are stripped; only the agent/exposure name remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists retained for KIT inhibitors, corticosteroids, antihistamines, retinoids, plus “(PRP)” and “(GHK-Cu)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies eight interactions and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol bullets (ER lines 296-318). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Conventional route, procedural route and baseline-biomarker correction are the only three bullets that specify an executable action. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects exist and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields populated; “1-2 mL twice daily”, “3-6 sessions, 2-6 weeks apart” and “Corrected first” all match ER text. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Time to effect (Practical Considerations), Duration and Post-discontinuation shedding (Discontinuation & Cycling) are the ER’s only temporal bullets. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered onset → maintenance → withdrawal, matching the ER’s own sequencing of the (undemonstrated) benefit. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; “None established”, “Indefinite” and “3-4 months” all trace to ER text. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Both entries reproduce ER benefit sub-headings (ER lines 157, 165, 169). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present in the Benefits card. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The 14.93 hairs/cm² and 57.1 hairs/cm² magnitudes and the risk-of-bias commentary are all omitted. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content in either benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High or Medium benefit; both spans carry style="display: none" with no empty-state text (lines 544, 547). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six entries reproduce ER risk sub-headings (ER lines 201, 207, 215, 221, 229, 233). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present in the Risks card. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The 10-patient phase I details, the 50% hyperpigmentation incidence and the minoxidil mean difference are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High risk; the span carries style="display: none" with no empty-state text (line 603). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All rows come from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 379-387). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarkers present: total hair density, terminal-to-vellus ratio, ferritin, 25-hydroxyvitamin D, TSH, serum zinc, serum total tryptase. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | “Baseline, then 3, 6 and 12 months; scalp photographs every 4 weeks during the first 3 months; deficiency panel repeated at 6 months if abnormal at baseline and annually thereafter.” matches ER line 377. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the ER’s “Qualitative markers worth tracking alongside the numbers” list (ER lines 391-395). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present and verbatim. |
Issues 24/08/2026 04:11
Pass rate 100.00%. No issues found.
Issues 24/08/2026 04:03
- 1.3 — Baseline-biomarker hedge dropped: [action_3_value] “Corrected first” (line 480) and [action_3_sub] (lines 484-486) drop the ER’s “in most protocols” qualifier (ER line 316), turning a description of common practice into an unqualified requirement.
- 2.8 / 4.5 — Free-text cells exceed compact budget: [time_1_sub] (175 characters, lines 503-507), [action_1_sub] (124 characters, lines 455-458), [action_3_sub] (122 characters, lines 483-486) and [marker_1_target] (79 characters, lines 645-648) were carried over near-verbatim from the ER instead of being condensed, pushing the sheet past the single-A4-page budget.
Fixes 24/08/2026 04:03
- 1.3 — Baseline-biomarker hedge restored: [action_3_sub] now reads “Ferritin, vitamin D and thyroid function in most protocols, since deficiency otherwise masks any topical effect”, restoring the ER’s “in most protocols” qualifier that had been dropped.
- 2.8 / 4.5 — Time-to-effect sub condensed: [time_1_sub] shortened from 175 to 136 characters (“No effect demonstrated, so no time course exists; growth-factor trials showed density changes at 3-6 months, full assessment at 12 months”).
- 2.8 / 4.5 — Conventional-approach sub condensed: [action_1_sub] shortened from 142 to 119 characters by dropping the redundant “continued for” and “exists” clauses while keeping the 6-12 month window.
- 2.8 / 4.5 — Hair-density target condensed: [marker_1_target] shortened to “No established target; usual trial threshold is a gain of 10 or more hairs/cm² from baseline”, which also repairs the dangling “from own baseline”.
Issues 24/08/2026 03:55
- 1.3 — Time-to-effect value overstated: [time_1_value] at line 500 headlines “3-6 months” for “Time to effect”, strengthening the ER’s “No effect has been demonstrated, so no time course exists” (ER line 351), where 3-6 months is offered only as a growth-factor-class guide.
Fixes 24/08/2026 03:55
- 1.3 — Time-to-effect value overstated: [time_1_value] changed from “3-6 months” to “None established”, and [time_1_sub] reworded to carry the 3-6 month figure explicitly as the growth-factor-class guide, matching the ER’s “no time course exists”.
Issues 24/08/2026 03:48
- 1.2 / 1.3 — Dropped “no established target” caution: [marker_1_target] (line 646) asserts “Gain of 10 or more hairs/cm² from own baseline”, while the ER’s biomarker table (line 387) states “No established target exists for this intervention” and frames the figure only as “the usual trial-level threshold”; the QRS drops the ER’s cautious phrasing and strengthens it into a stated target.
Fixes 24/08/2026 03:48
- 1.2 / 1.3 — Restored “no established target” caution: [marker_1_target] changed from “Gain of 10 or more hairs/cm² from own baseline” to “No established target; usual trial-level threshold is a gain of 10 or more hairs/cm² from own baseline”, matching the ER’s cautious phrasing at line 387.